Medical Developments International

Medical Developments International (MDI) is an Australia-based global healthcare company specializing in acute pain management and respiratory products. The company is registered in over 28 countries and serves acute trauma, procedural pain, asthma, and COPD patient populations. MDI manufactures and supplies analgesia delivery systems for acute pain indications, with regulatory approvals including HPRA (Health Products Regulatory Authority) clearance for pediatric use of Penthrox. The company also develops and distributes respiratory devices for chronic disease management. MDI operates with over 80 employees and generated $33.2 million in revenue in FY24. The company maintains an active product development pipeline and engages in strategic partnerships to expand market access, including recent distributor agreements for European markets. As a publicly listed entity on the Australian Securities Exchange (ASX: MVP), MDI maintains investor relations and regulatory compliance across multiple jurisdictions. Products are marketed through local registration processes with regional distribution partners.